NASDAQ:EXEL - Exelixis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.75
  • Forecasted Upside: 55.06 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.28 (1.27%)
1 month | 3 months | 12 months
Get New Exelixis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXEL

Average Price Target: $34.75
▲ +55.06% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $34.75, with a high forecast of $47.00 and a low forecast of $26.00. The average price target represents a 55.06% upside from the last price of $22.41.


The current consensus among 9 polled investment analysts is to buy stock in Exelixis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021HC WainwrightInitiated CoverageBuy$47.00Medium
4/19/2021Morgan StanleyLower Price TargetEqual Weight$27.00 ➝ $26.00Low
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$30.00High
3/11/2021Wolfe ResearchInitiated CoverageOutperform$35.00Medium
2/16/2021Piper SandlerBoost Price TargetOverweight$33.00 ➝ $36.00Low
1/15/2021William BlairReiterated RatingBuyN/A
12/16/2020Morgan StanleyLower Price TargetEqual Weight$29.00 ➝ $27.00Low
10/26/2020Stifel NicolausBoost Price TargetHold$26.00 ➝ $27.00Low
9/22/2020Morgan StanleyBoost Price TargetEqual Weight$23.00 ➝ $29.00Low
9/21/2020OppenheimerBoost Price TargetOutperform$33.00 ➝ $37.00Low
9/21/2020Piper SandlerBoost Price TargetOverweight$30.00 ➝ $33.00High
8/14/2020William BlairReiterated RatingBuyHigh
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$22.00 ➝ $23.00Medium
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$21.00 ➝ $22.00Low
7/8/2020SunTrust BanksReiterated RatingBuy$40.00Low
6/2/2020William BlairReiterated RatingBuyMedium
6/1/2020OppenheimerInitiated CoverageBuy$28.00 ➝ $32.00Medium
5/14/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$35.00 ➝ $40.00High
5/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$20.00 ➝ $27.00Medium
5/6/2020Needham & Company LLCReiterated RatingBuy$33.00Medium
5/6/2020Piper SandlerBoost Price Target$23.00 ➝ $30.00Medium
5/6/2020Morgan StanleyBoost Price TargetEqual Weight$20.00 ➝ $21.00Low
4/21/2020GuggenheimBoost Price Target$27.00 ➝ $32.00High
4/21/2020BarclaysReiterated RatingBuy$30.00High
4/21/2020OppenheimerBoost Price TargetOutperform$25.00 ➝ $28.00High
4/20/2020Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $33.00Medium
3/25/2020Piper SandlerReiterated RatingBuy$23.00High
3/13/2020William BlairReiterated RatingBuyLow
3/4/2020BarclaysInitiated CoverageOverweight$26.00Medium
2/27/2020Piper SandlerLower Price Target$35.00 ➝ $23.00Medium
2/26/2020BMO Capital MarketsBoost Price TargetMarket Perform$19.00 ➝ $20.00Medium
2/26/2020Stifel NicolausBoost Price TargetHold$21.00 ➝ $23.00Medium
2/26/2020CowenReiterated RatingBuyMedium
2/14/2020William BlairReiterated RatingBuyLow
2/11/2020Piper SandlerReiterated RatingBuy$35.00High
1/27/2020Needham & Company LLCReiterated RatingBuy$28.00Low
1/13/2020SunTrust BanksInitiated CoverageBuy$31.00High
1/13/2020Bank of AmericaReiterated RatingBuy$22.00 ➝ $21.00High
1/12/2020CowenReiterated RatingBuy$23.00Low
1/9/2020William BlairReiterated RatingBuyLow
12/13/2019Needham & Company LLCReiterated RatingBuy$30.00Low
12/13/2019CowenReiterated RatingBuy$23.00Low
11/13/2019Bank of AmericaInitiated CoverageBuy$22.00High
10/31/2019Piper Jaffray CompaniesLower Price Target$45.00 ➝ $35.00High
10/15/2019GuggenheimLower Price TargetBuy$33.00 ➝ $25.00High
10/8/2019BMO Capital MarketsLower Price TargetMarket Perform$23.00 ➝ $19.00Medium
8/1/2019Stifel NicolausBoost Price TargetHold$22.00 ➝ $23.00High
7/31/2019CowenSet Price TargetBuy$25.00N/A
7/15/2019CowenSet Price TargetBuy$25.00Medium
5/2/2019Morgan StanleySet Price TargetHold$27.00High
4/23/2019CowenReiterated RatingBuy$29.00High
3/19/2019OppenheimerReiterated RatingBuyLow
3/18/2019Morgan StanleyUpgradeUnderweight ➝ Equal Weight$24.80High
3/1/2019Piper Jaffray CompaniesReiterated RatingOverweight$48.00Low
2/26/2019CowenReiterated RatingBuy$29.00Low
2/22/2019BMO Capital MarketsInitiated CoverageMarket Perform$23.00Low
2/13/2019OppenheimerLower Price TargetOutperform$40.00 ➝ $31.00Low
11/15/2018OppenheimerSet Price TargetBuy$40.00Medium
11/5/2018Piper Jaffray CompaniesLower Price TargetOverweight$29.00 ➝ $26.00Low
11/1/2018OppenheimerSet Price TargetBuy$40.00High
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/17/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$22.00High
9/10/2018Morgan StanleyInitiated CoverageUnderweight ➝ Underweight$19.00Medium
8/1/2018Stifel NicolausLower Price TargetHold ➝ Hold$29.00 ➝ $25.00Low
5/11/2018Needham & Company LLCLower Price TargetBuy ➝ Buy$33.00 ➝ $30.00High
5/10/2018Piper Jaffray CompaniesLower Price TargetOverweight$33.00 ➝ $29.00High
5/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$30.00 ➝ $29.00High
4/11/2018William BlairReiterated RatingBuyLow
2/27/2018Stifel NicolausBoost Price TargetHold ➝ Hold$29.00 ➝ $30.00High
2/27/2018OppenheimerUpgradeMarket Perform ➝ Outperform$40.00High
2/27/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
2/12/2018William BlairReiterated RatingOutperformMedium
1/17/2018OppenheimerReiterated RatingHoldHigh
1/4/2018OppenheimerReiterated RatingHoldMedium
12/21/2017SunTrust BanksReiterated RatingBuy$38.00High
12/19/2017OppenheimerReiterated RatingHoldLow
10/17/2017Needham & Company LLCBoost Price TargetBuy$30.00 ➝ $33.00N/A
10/17/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $39.00N/A
10/17/2017Stifel NicolausReiterated RatingHold$26.00N/A
10/16/2017Piper Jaffray CompaniesReiterated RatingOverweightN/A
10/16/2017OppenheimerReiterated RatingHoldN/A
10/16/2017SunTrust BanksBoost Price TargetBuy ➝ Buy$32.00 ➝ $35.00N/A
10/2/2017Needham & Company LLCReiterated RatingBuy$30.00Low
9/25/2017OppenheimerReiterated RatingHoldMedium
9/22/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$34.00 ➝ $28.00High
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$32.00Medium
9/12/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $30.00Medium
9/10/2017OppenheimerReiterated RatingHoldMedium
9/10/2017Piper Jaffray CompaniesReiterated RatingBuy$29.00Medium
9/7/2017Stifel NicolausReiterated RatingHold$26.00Low
8/10/2017CowenReiterated RatingOutperformMedium
8/3/2017Piper Jaffray CompaniesReiterated RatingBuy$29.00Low
8/3/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$26.00 ➝ $29.00Medium
8/3/2017Stifel NicolausReiterated RatingHold$26.00High
7/27/2017William BlairReiterated RatingOutperformMedium
7/13/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$33.00Medium
6/26/2017William BlairReiterated RatingOutperformMedium
6/16/2017William BlairReiterated RatingOutperformLow
6/12/2017OppenheimerInitiated CoverageHoldLow
6/5/2017OppenheimerReiterated RatingHoldLow
5/4/2017OppenheimerReiterated RatingMarket PerformMedium
4/21/2017OppenheimerReiterated RatingMarket PerformHigh
3/31/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$28.00Medium
3/16/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformHigh
3/16/2017OppenheimerInitiated CoverageMarket PerformHigh
3/1/2017William BlairReiterated RatingOutperformN/A
2/28/2017Stifel NicolausDowngradeBuy ➝ Hold$22.00N/A
1/28/2017William BlairReiterated RatingOutperformN/A
1/24/2017CowenReiterated RatingOutperformN/A
11/8/2016CowenReiterated RatingOutperformN/A
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$17.00N/A
10/12/2016CowenReiterated RatingOutperformN/A
10/10/2016Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightN/A
10/7/2016SVB LeerinkReiterated RatingPositive$15.00N/A
9/28/2016SVB LeerinkReiterated RatingOutperform$15.00N/A
9/28/2016S&P Equity ResearchBoost Price Target$13.41 ➝ $15.57N/A
9/20/2016SVB LeerinkReiterated RatingOutperform$12.00N/A
9/15/2016Stifel NicolausBoost Price TargetBuy$12.00 ➝ $15.00N/A
9/15/2016William BlairReiterated RatingOutperformN/A
9/7/2016SVB LeerinkReiterated RatingPositive$12.00N/A
8/29/2016SVB LeerinkReiterated RatingOutperform$12.00N/A
8/18/2016SVB LeerinkReiterated RatingOutperform$12.00N/A
8/10/2016CowenReiterated RatingBuyN/A
8/4/2016SVB LeerinkReiterated RatingOutperform$10.00 ➝ $12.00N/A
8/4/2016Piper Jaffray CompaniesReiterated RatingNeutral$5.00 ➝ $8.00N/A
8/4/2016Stifel NicolausBoost Price TargetBuy$10.00 ➝ $12.00N/A
7/19/2016SVB LeerinkReiterated RatingBuy$10.00N/A
6/21/2016SVB LeerinkReiterated RatingOutperform$8.00 ➝ $10.00N/A
(Data available from 6/20/2016 forward)
Exelixis logo
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $22.41
Low: $21.73
High: $22.48

50 Day Range

MA: $23.67
Low: $22.06
High: $25.56

52 Week Range

Now: $22.41
Low: $18.18
High: $27.35


2,887,089 shs

Average Volume

1,926,697 shs

Market Capitalization

$7.02 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Exelixis?

The following Wall Street sell-side analysts have issued stock ratings on Exelixis in the last twelve months: Credit Suisse Group AG, HC Wainwright, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, SunTrust Banks, Inc., TheStreet, William Blair, and Wolfe Research.
View the latest analyst ratings for EXEL.

What is the current price target for Exelixis?

8 Wall Street analysts have set twelve-month price targets for Exelixis in the last year. Their average twelve-month price target is $34.75, suggesting a possible upside of 55.1%. HC Wainwright has the highest price target set, predicting EXEL will reach $47.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $26.00 for Exelixis in the next year.
View the latest price targets for EXEL.

What is the current consensus analyst rating for Exelixis?

Exelixis currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXEL will outperform the market and that investors should add to their positions of Exelixis.
View the latest ratings for EXEL.

What other companies compete with Exelixis?

How do I contact Exelixis' investor relations team?

Exelixis' physical mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company's listed phone number is 650-837-7000 and its investor relations email address is [email protected] The official website for Exelixis is